Abstract: The invention relates to the use of viral vectors able to stably integrate into the genome of thymic stromal cells, or of intrathymic lymphocytes or lymphocytes precursors, for the manufacture of a medicine intended for intrathymic administration in the frame of the prevention or treatment of genetic immunodeficiencies, acquired immunodeficiencies, or for the induction of immune tolerance of the organism to self or non-self gene products, cells or tissues, or for the prevention or treatment of autoimmune diseases.
Type:
Grant
Filed:
June 3, 2005
Date of Patent:
March 12, 2013
Assignees:
Centre National de la Recherche Scientifique, Universite Pierre et Marie Curie, Universite Montpellier II
Abstract: The present invention relates to a modified pig as a model for studying Alzheimer's disease. The modified pig model displays one or more phenotypes associated with Alzheimer's disease. Disclosed is also a modified pig comprising a modified human and/or porcine APP gene, and/or PS1 gene, and/or a transcriptional and/or translational product or part thereof. The invention further relates to methods for producing the modified pig; and methods for evaluating the effect of a therapeutical treatment of Alzheimer's disease; methods for screening the efficacy of a pharmaceutical composition; and a method for treatment of a human being suffering from Alzheimer's disease are disclosed.
Type:
Grant
Filed:
March 6, 2008
Date of Patent:
March 5, 2013
Assignee:
Aarhus Universitet
Inventors:
Arne Lund Jørgensen, Ida Elisabeth Holm, Anders Lade Nielsen, Marianne Gregers Johansen, Jannik Ejnar Jakobsen
Abstract: Methods described include methods of treating T1DM, the method comprising delivering a therapeutic amount of ?-MSC to a subject in need thereof. Further disclosed are fusion cells comprising and MSC and a second cell wherein the nuclei of the MSC and the second cell are not fused in the fusion cell.
Type:
Grant
Filed:
February 17, 2012
Date of Patent:
February 12, 2013
Assignees:
University of Utah Research Foundation, U.S. Department of Veteran Affairs
Abstract: There is provided a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of a Notch gene. Specifically, the invention provides a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells in vitro, which method comprises introducing a Notch gene and/or a Notch signaling related gene into the cells, wherein the finally obtained differentiated cells are the result of cell division of the bone marrow stromal cells into which the Notch gene and/or Notch signaling related gene have been introduced. The invention also provides a method of inducing further differentiation of the differentiation-induced neural cells to dopaminergic neurons or acetylcholinergic neurons. The invention yet further provides a treatment method for neurodegenerative and skeletal muscle degenerative diseases which employs neural precursor cells, neural cells or skeletal muscle cells produced by the method of the invention.
Type:
Grant
Filed:
September 10, 2009
Date of Patent:
January 29, 2013
Assignee:
SanBio, Inc.
Inventors:
Mari Dezawa, Hajime Sawada, Hiroshi Kanno, Masahiko Takano
Abstract: Filamentous bacteriophage which does not display an antibody or a non-filamentous bacteriophage antigen on its surface is used to inhibit or treat brain inflammation associated with amyloid deposits and/or involving activated microglia, to inhibit the formation of amyloid deposits, and to disaggregate pre-formed amyloid deposits.
Abstract: The invention concerns a human stem cell isolated from the full depth of human cartilage tissue and/or isolated from aged human cartilage; and uses thereof.
Type:
Grant
Filed:
February 6, 2008
Date of Patent:
January 22, 2013
Assignee:
University College Cardiff Consultants Limited
Inventors:
Charles William Archer, Samantha Nichola Haven, Gary Dowthwaite
Abstract: The present invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries.
Type:
Grant
Filed:
June 16, 2008
Date of Patent:
January 15, 2013
Assignee:
Garnet BioTherapeutics, Inc.
Inventors:
Gene Kopen, Joseph Wagner, Vanessa Ragaglia, Baron Heimbach, Richard S. Gore
Abstract: An isolated primate embryonic cell is provided as well as cell cultures and cell lines derived therefrom. Also provided are methods of generating and using such cells.
Type:
Grant
Filed:
October 11, 2005
Date of Patent:
January 15, 2013
Assignee:
Technion Research & Development Foundation Ltd.
Abstract: Methods of generating and expanding proliferative, multipotent connective tissue progenitor cells from embryonic stem cells and embryoid bodies are provided. Also provided are methods of generating functional tendon grafts in vitro and bone, cartilage and connective tissues in vivo using the isolated cell preparation of connective tissue progenitor cells.
Type:
Grant
Filed:
January 11, 2007
Date of Patent:
January 1, 2013
Assignee:
Technion Research & Development Foundation Ltd.
Abstract: Disclosed are methods of enhancing recovery from joint surgery, comprising administering to the joint during surgery a composition comprising stem or progenitor cells in an amount effective to enhance recovery, and a pharmaceutically acceptable carrier.
Abstract: Provided is a method for the derivation of neural stem cells (NSCs) from embryonic stem cells (ESCs) and the use of the NSCs for treatment of various neural disorders. The NSCs that are derived from the ESCs are tissue-specific multipotent NSCs with a stable growth rate, unlimited self-renewal capacity, and a predictable differentiation profile. Being both non-tumorigenic and engraftable, the NSCs of the present invention have utility in repopulation stroke-damaged tissue. The NSCs of the present invention may be differentiated to produce tyrosine-hydroxylase expressing neurons, which may be used as a source of dopaminergic neurons for subjects suffering from a condition characterized by dopaminergic dysfunction, such as Parkinson's disease.
Type:
Grant
Filed:
July 29, 2008
Date of Patent:
December 25, 2012
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: The invention provides acellular tissue matrices made from collagen-containing tissues of animals genetically modified so as to be deficient in the galactose 1,3-galactose epitope and methods of making and using such acellular tissue matrices.
Type:
Grant
Filed:
September 16, 2010
Date of Patent:
December 4, 2012
Assignee:
LifeCell Corporation
Inventors:
David J. McQuillan, Edward S. Griffey, Herbert Daniel Beniker, Hui Xu
Abstract: A cell culture comprising human foreskin cells, the human foreskin cells being capable of maintaining stem cells in an undifferentiated state when co-cultured therewith.
Type:
Grant
Filed:
January 28, 2010
Date of Patent:
November 27, 2012
Assignee:
Technion Research & Development Foundation Ltd.
Abstract: The present invention relates to the induction of differentiation in stem cells to cardiomyocytes and factors such as prostaglandin alone or in combination with other factors including essential minerals selected from the group including transferrin and selenium, small molecules selected from the group including a p38 MAPK inhibitor such as SB203580 and protein growth factors of the FGF, IGF and BMP families such as but not limited to IGF1, FGF2, BMP2, BMP4 and BMP6. and insulin that influence the process of differentiation to cardiomyocytes. Media that is appropriate for the induction of differentiation of cardiomyocytes from stem cells is also provided wherein the media contains these factors. The use of cardiomyocytes and cardiac progenitors produced by the directed differentiation in transplantation and screening for cardiac compounds is also provided.
Type:
Grant
Filed:
December 22, 2006
Date of Patent:
November 27, 2012
Inventors:
Bruce Paul Davidson, Ralph Eberhard Graichen, Robert Zweigerdt, Xiuqin Xu, Christine Lindsay Mummery, William Sun
Abstract: The invention relates to compositions, kits, and methods for cancer therapy using recombinant MVA viruses encoding a tumor-associated antigen, such as HER-2, particularly in combination with taxanes. The taxanes can be administered prior to, at the same time as, or after the recombinant MVA virus.
Abstract: Disclosed is a method for coexpressing IL-12 (interleukin-12) and IL-23 (interleukin-23), which comprises the steps of: (a) preparing vectors comprising monocistronic expression constructs of each of nucleotide sequences encoding the p35 subunit, the p40 subunit and the p19 subunit, or preparing a vector comprising a polycistronic expression construct of nucleotide sequences encoding the p35 subunit, the p40 subunit and the p19 subunit; (b) transforming the expression constructs into a host cell; and (c) culturing the transformed host cell to obtain IL-12 and IL-23, a vector for coexpressing IL-12 and IL-23, and a pharmaceutical anti-tumor composition comprising the vectors.
Abstract: The present invention relates to a skin equivalent and a method for producing the same, wherein the skin equivalent comprises a scaffold and stem/progenitor cells isolated from the amniotic membrane of umbilical cord. These stem/progenitor cells may be mesenchymal (UCMC) and/or epithelial (UCEC) stem cells, which may then be further differentiated to fibroblast and keratinocytes. Further described is a method for isolating stem/progenitor cells from the amniotic membrane of umbilical cord, wherein the method comprises separating the amniotic membrane from the other components of the umbilical cord in vitro, culturing the amniotic membrane tissue under conditions allowing cell proliferation, and isolating the stem/progenitor cells from the tissue cultures. The invention also refers to therapeutic uses of these skin equivalents.
Abstract: The present invention is directed to pluripotent cells that can be readily expanded in culture on tissue culture substrate that is not pre-treated with protein or an extracellular matrix, and do not require a feeder cell line. The present invention also provides methods to derive the pluripotent cell line from human embryonic stem cells.